全文获取类型
收费全文 | 7025篇 |
免费 | 457篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 245篇 |
妇产科学 | 158篇 |
基础医学 | 870篇 |
口腔科学 | 78篇 |
临床医学 | 947篇 |
内科学 | 1297篇 |
皮肤病学 | 174篇 |
神经病学 | 718篇 |
特种医学 | 277篇 |
外科学 | 758篇 |
综合类 | 30篇 |
一般理论 | 4篇 |
预防医学 | 786篇 |
眼科学 | 66篇 |
药学 | 440篇 |
中国医学 | 13篇 |
肿瘤学 | 564篇 |
出版年
2024年 | 8篇 |
2023年 | 65篇 |
2022年 | 102篇 |
2021年 | 199篇 |
2020年 | 153篇 |
2019年 | 216篇 |
2018年 | 260篇 |
2017年 | 215篇 |
2016年 | 166篇 |
2015年 | 200篇 |
2014年 | 259篇 |
2013年 | 402篇 |
2012年 | 594篇 |
2011年 | 601篇 |
2010年 | 313篇 |
2009年 | 293篇 |
2008年 | 507篇 |
2007年 | 476篇 |
2006年 | 461篇 |
2005年 | 423篇 |
2004年 | 395篇 |
2003年 | 346篇 |
2002年 | 315篇 |
2001年 | 45篇 |
2000年 | 34篇 |
1999年 | 43篇 |
1998年 | 70篇 |
1997年 | 53篇 |
1996年 | 35篇 |
1995年 | 23篇 |
1994年 | 25篇 |
1993年 | 28篇 |
1992年 | 12篇 |
1991年 | 28篇 |
1990年 | 14篇 |
1989年 | 12篇 |
1988年 | 8篇 |
1987年 | 11篇 |
1986年 | 8篇 |
1985年 | 11篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 9篇 |
1981年 | 12篇 |
1980年 | 5篇 |
1978年 | 5篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1974年 | 2篇 |
1969年 | 2篇 |
排序方式: 共有7491条查询结果,搜索用时 15 毫秒
51.
Laura M. Carlson Michelle Angrish Avanti V. Shirke Elizabeth G. Radke Brittany Schulz Andrew Kraft Richard Judson Grace Patlewicz Robyn Blain Cynthia Lin Nicole Vetter Courtney Lemeris Pamela Hartman Heidi Hubbard Xabier Arzuaga Allen Davis Laura V. Dishaw Ingrid L. Druwe Hillary Hollinger Ryan Jones J. Phillip Kaiser Lucina Lizarraga Pamela D. Noyes Michele Taylor Andrew J. Shapiro Antony J. Williams Kristina A. Thayer 《Environmental health perspectives》2022,130(5)
Background: Per- and polyfluoroalkyl substances (PFAS) are a large class of synthetic (man-made) chemicals widely used in consumer products and industrial processes. Thousands of distinct PFAS exist in commerce. The 2019 U.S. Environmental Protection Agency (U.S. EPA) Per- and Polyfluoroalkyl Substances (PFAS) Action Plan outlines a multiprogram national research plan to address the challenge of PFAS. One component of this strategy involves the use of systematic evidence map (SEM) approaches to characterize the evidence base for hundreds of PFAS.Objective: SEM methods were used to summarize available epidemiological and animal bioassay evidence for a set of PFAS that were prioritized in 2019 by the U.S. EPA’s Center for Computational Toxicology and Exposure (CCTE) for in vitro toxicity and toxicokinetic assay testing.Methods: Systematic review methods were used to identify and screen literature using manual review and machine-learning software. The Populations, Exposures, Comparators, and Outcomes (PECO) criteria were kept broad to identify mammalian animal bioassay and epidemiological studies that could inform human hazard identification. A variety of supplemental content was also tracked, including information on in vitro model systems; exposure measurement–only studies in humans; and absorption, distribution, metabolism, and excretion (ADME). Animal bioassay and epidemiology studies meeting PECO criteria were summarized with respect to study design, and health system(s) were assessed. Because animal bioassay studies with exposure duration (or reproductive/developmental study design) were most useful to CCTE analyses, these studies underwent study evaluation and detailed data extraction. All data extraction is publicly available online as interactive visuals with downloadable metadata.Results: More than 40,000 studies were identified from scientific databases. Screening processes identified 44 animal and 148 epidemiology studies from the peer-reviewed literature and 95 animal and 50 epidemiology studies from gray literature that met PECO criteria. Epidemiological evidence (available for 15 PFAS) mostly assessed the reproductive, endocrine, developmental, metabolic, cardiovascular, and immune systems. Animal evidence (available for 40 PFAS) commonly assessed effects in the reproductive, developmental, urinary, immunological, and hepatic systems. Overall, 45 PFAS had evidence across animal and epidemiology data streams.Discussion: Many of the PFAS were data poor. Epidemiological and animal evidence were lacking for most of the PFAS included in our search. By disseminating this information, we hope to facilitate additional assessment work by providing the initial scoping literature survey and identifying key research needs. Future research on data-poor PFAS will help support a more complete understanding of the potential health effects from PFAS exposures. https://doi.org/10.1289/EHP10343 相似文献
52.
53.
Marielle E. Yohe Christine M. Heske Elizabeth Stewart Peter C. Adamson Nabil Ahmed Cristina R. Antonescu Eleanor Chen Natalie Collins Alan Ehrlich Rene L. Galindo Berkley E. Gryder Heidi Hahn Sharon Hammond Mark E. Hatley Douglas S. Hawkins Madeline N. Hayes Andrea Hayes‐Jordan Lee J. Helman Simone Hettmer Myron S. Ignatius Charles Keller Javed Khan David G. Kirsch Corinne M. Linardic Philip J. Lupo Rossella Rota Jack F. Shern Janet Shipley Sivasish Sindiri Stephen J. Tapscott Christopher R. Vakoc Leonard H. Wexler David M. Langenau 《Pediatric blood & cancer》2019,66(10)
Overall survival rates for pediatric patients with high‐risk or relapsed rhabdomyosarcoma (RMS) have not improved significantly since the 1980s. Recent studies have identified a number of targetable vulnerabilities in RMS, but these discoveries have infrequently translated into clinical trials. We propose streamlining the process by which agents are selected for clinical evaluation in RMS. We believe that strong consideration should be given to the development of combination therapies that add biologically targeted agents to conventional cytotoxic drugs. One example of this type of combination is the addition of the WEE1 inhibitor AZD1775 to the conventional cytotoxic chemotherapeutics, vincristine and irinotecan. 相似文献
54.
JD Kuhlmann H Schwarzenbach P Wimberger M Poetsch R Kimmig S Kasimir-Bauer 《BMC cancer》2012,12(1):325
ABSTRACT: BACKGROUND: We recently showed that LOH proximal to M6P/IGF2R locus (D6S1581) in primary ovarian tumors is predictive for the presence of disseminated tumor cells (DTC) in the bone marrow (BM). For therapy-monitoring, it would be highly desirable to establish a blood-based biomarker. Therefore, we quantified circulating DNA (cirDNA) in sera of 63 ovarian cancer patients before surgery and after chemotherapy, measured incidence of LOH at four cancer-relevant chromosomal loci, correlated LOH with tumor cell spread to the BM and evaluated prognostic significance of LOH. Patients and Methods: cirDNA was fractionated into high- and low molecular-weight fraction (HMWF, LMWF) for LOH-profiling, utilizing PCR-based fluorescence microsatellite analysis. BM aspirates were analyzed for DTC by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3. RESULTS: cirDNA levels in the HMWF before surgery were predictive for residual tumor load (p=0.017). After chemotherapy, we observed a significant decline of cirDNA in the LMWF (p=0.0001) but not in the HMWF. LOH was prevalently detected in the LMWF with an overall frequency of 67 %, only moderately ablating after chemotherapy (45 %). Before surgery, LOH in the LMWF at marker D10S1765 and D13S218 significantly correlated with tumor grading and FIGO stage (p=0.033, p=0.004, respectively). In both combined fractions, LOH at D6S1581 additionally associated with overall survival (OS) (p=0.030). Moreover, solely LOH at D10S1765 in LMWF after therapy correlated with DTC in BM after therapy (p=0.017). CONCLUSION: We demonstrate the applicability and necessity of DNA-fractionation prior to analyzing circulating LOH and identify LOH at D10S1765 and D6S1581 as novel blood-based biomarkers for ovarian cancer, being relevant for therapy-monitoring. 相似文献
55.
56.
57.
BACKGROUND: Lichen sclerosus (LS) is a chronic inflammatory skin condition, which most commonly causes dysuria, pruritus and soreness of the vulval and perianal areas. Potent topical corticosteroids are used for the treatment of LS, but it is well known that they inhibit collagen synthesis and cause skin atrophy as a side effect. METHODS: The present pilot study evaluated the efficacy and safety of pimecrolimus cream 1% applied twice daily for up to 6 months in 29 women with severe LS. RESULTS: Of the 26 subjects who completed the follow-up period, 42% (11/26) were in complete remission with relief from itchiness, pain and inflammation. A 3.5-fold increase in type I collagen synthesis and a 7.5-fold increase in type III collagen synthesis of the affected areas was detected after 2 months of pimecrolimus treatment. There were no systemic adverse reactions, although mild local skin reactions were reported by 50% of the patients. Blood concentrations of pimecrolimus were checked in 10/26 patients (39%) and were undetectable in all cases. CONCLUSIONS: Patient-applied 1% pimecrolimus cream is safe and effective for the treatment of LS. 相似文献
58.
59.
60.
Heidi N. Hilton N. Santucci A. Silvestri S. Kantimm L. I. Huschtscha J. D. Graham C. L. Clarke 《Breast cancer research and treatment》2014,143(3):423-433
The epithelium of the human breast is made up of a branching ductal–lobular system, which is lined by a single layer of luminal cells surrounded by a contractile basal cell layer. The co-ordinated development of stem/progenitor cells into these luminal and basal cells is fundamentally important for breast morphogenesis. The ovarian steroid hormones, progesterone (P) and 17β-estradiol, are critical in driving this normal breast development, yet ovarian activity has also been shown to be a major driver of breast cancer risk. We previously demonstrated that P treatment increases proliferation and augments the number of progenitor-like cells, and that the progesterone receptor (PR) is also expressed in the bipotent progenitor-enriched subfraction. Here we demonstrate that PR is expressed in a subset of CD10+ basal cells and that P stimulates this CD10+ cell compartment, which is enriched for bipotent progenitor activity. In addition, we have shown that P stimulates progenitor cells in human breast cancer cell lines and expands the cancer stem cell population via increasing the stem-like CD44+ population. As changes in cell type composition are one of the hallmark features of breast cancer progression, the demonstration that progenitor cells are stimulated by P in both normal breast and in breast cancer cells has critical implications in discerning the mechanisms of how P increases breast cancer risk. 相似文献